A decade after the Randomized Controlled Studies (as RCT’s) on Direct Oral Anticoagulants as DOAC’s, or as called by other names as: • NOAC’s (as novel oral anticoagulants or non- vitamin K dependent oral anticoagulants) or • TSOAC (as target specific oral anticoagulants), have been published what have we learned? According to the metanalyses of those RCT’s (comparison to warfarin \ VKA and not a direct comparison) all of the DOAC’s are either superior to warfarin (dabigatran 150 mg bid, apixaban) or noninferior (rivaroxaban, edoxaban, dabigatran 110 mg bid) in the reduction of stroke.